

CURRICULUM VITAE

Name: Asterios S. Tsiftoglou
Address: 33 Ipirou Street , Panorama
55236, Thessaloniki, Greece
Date of Birth: October 8, 1948
Place of Birth: Kilkis, Greece
Marital Status: Married/Two children

Present Address

Asterios S. Tsiftoglou, Ph.D.
Professor of Pharmacology
Department of Pharmaceutical Sciences
Aristotle University of Thessaloniki,
Thessaloniki, 54124, Greece
Tel 0030-2310-997631
Fax. 0030-2310-997618
e-mail tsif@pharm.auth.gr

Education:

1972 Diploma in Pharmaceutical Sciences
Aristotle University of Thessaloniki, Greece
1975 M. Sci., M. Phill. Yale University (Pharmacology)
1979 Ph.D. Yale University (Pharmacology)

Research Fellowships:

1978-1979 Health Sciences Fund Fellow, Department of Biology and
Center for Cancer Research Massachusetts Institute of
Technology, Cambridge, MA.
1979-1981 Damon Runyon-Walter Winchell Cancer Research Fellow
Department of Biology and Center for Cancer Research,
Massachusetts Institute of Technology, Cambridge, MA.

Academic Appointments:

1981-1984 Visiting Scientist (part-time), Center for Cancer Research,
MIT, Cambridge, MA.
1981-1982 Instructor in Medicine, Harvard Medical School
1982-1985 Assistant Professor of Medicine, Harvard Medical School,
Boston, MA.
1985-1989 Associate Professor of Pharmacology, Dept. of Pharmaceu-
tical Sciences, Aristotle University of Thessaloniki, Greece.
1989-1993 Professor of Pharmacology and Chairman, Dept. of
Pharmaceutical Sciences, Aristotle University of Thessaloniki,
Greece.
1993- Professor of Pharmacology, Dept. of Pharmaceutical Sciences,
Aristotle University of Thessaloniki (AUTH), Greece.
1987-1993/2005-present Chairman of the Dept. of Pharmaceutical Sciences (AUTH).

Hospital Appointments

1981-1985 Research Associate in Medicine, Beth Israel Hospital, Boston, MA.

Honors and Grant Awards:

1967-1971 Greek National Foundation Scholarship
1972-1976 Yale University Graduate School Scholarship
1976 Amer. Cancer Soc. Predoctoral Summer Scholarship
1978-1979 Health Sciences Fund Fellowship
1979-1981 Damon Runyon-Walter Winchell Cancer Res. Award
1981-1982 Beth Israel Hospital Biomedical Research Award
1981-1982 Milton Fund-Harvard University Research Award
1982-1983 Leukemia Research Foundation Award
1983-1984 Beth Israel Hospital Biomedical Research Award
1983-1984 American Cancer Soc. (Mass. Div.) Research Award
1984-1986 NIH Young Investigator Award
1984-1986 Junior Faculty Research Award of American Cancer Society (Natl.)
1989-1991 Commission of European Community Research Grant (Biotechnology Action Program) (BAP)
1991-1993 Commission of European Community Research Grant (BRIDGE R and D Program on Biotechnology)
1994-1997 Greek Secretariat for Science and Technology (EPET II)
1998-2001 Greek Secretariat for Science and Technology (EKBAN)
2000-2002 Greek Secretariat for Science and Technology (PENED)
2000-2005 European Union (Cost 844)
2003-2005 STEMNET (EPAN)
2003-2006 IRAKLEITOS
2011- EATRIS-GR

Membership in Scientific Societies:

1975- Sigma XI
1977- American Society for Cell Biology
1979- New York Academy of Sciences
1980- Hellenic Society of Biochemistry and Molecular Biology
1981- American Association for Cancer Research
1986- European Association for Cancer Research
1989- American Society of Microbiology
1998- Hellenic Society of Pharmacology
2004 European Cell Death Organization (ECDO)
2005 International Society for Cell Therapy (ISCT)

Other Professional Activities:

1985 Member of Study Section Review Committee for Grants in Greek Science and Technology Ministry.
1986 Member of an Ad Hoc Study Section Review Committee for Grants in Commission of European Community (CEG).
1988 Member of an Ad Hoc Study Section Review Committee for Grants in Commission of European Community (CEG).
1990 Member of an Ad Hoc Study Section Review Committee for Grants by the Greek Secretariat for Science and Technology.
1998 National Representative of the European Cancer Forum.
1998-2001 Member of the Committee of Bioethics of Ministry of

| | |
|-----------------|--|
| 2004 to present | Development in Greece. Core Member of Biologics Working Party (BWP) and Cell Based Working Party (CBWP) of EMEA, London |
| 2008 to present | Chairman of the Biotechnology Medicinal Products, Greek National Organization for Medicines (EOF) |
| 2009 to present | Core Member of the Committee for Advanced Therapies (CAT) of the European Medicine Agency (EMA, London) |

Reviewer in Scientific Journals

J Cell Biochemistry, Biochemical Pharmacology, Oncogene, Oncology Research, Regenerative Medicine, Biotechnology J, J of Hematological Malignancies, Leukemia Res, Cancer Res , International Journal of Cancer , Cell Proliferation, Biodrugs, Apoptosis, European Journal Of Hematology. European Journal Of Medicinal Chemistry. Prof. A.Tsiftoglou is also a member of the Editorial Board of the International Journal "Oncology Research" and Journal of Hematological Malignancies.

Research achievements in the last 10 years

- Molecular analysis and gene expression patterns during erythroid differentiation of mouse and human leukemic cells (sub – programs of erythroid maturation, expression of globin genes as well as ribosomal genes, the role of hypomethylation of RNA and DNA and exploration of the role of commitment of pro-erythroid cells).
- Analysis of the pivotal role of heme as regulator of cell survival and as regulator of transcription of globin and non globin genes.
- Detection of novel targets of anthracyclines and other antineoplastics (Imatinib, Nilotinib) on the functional role of cytochrome c oxidase in leukemia cell death and cardiovascular toxicity.
- The application of rapid PCR cloning in fusion tag vectors and expression of several cytokines (inteleukines, GM-CSF, TNF, NGF, SCF, SCo2 protein).
- Protein Transduction Domain (PTD) technology for the intracellular delivery of recombinant therapeutic proteins

Selected Invited Talks

In: Universities, Research Centers, Pharmaceutical Industry, International Conferences, Workshops

- Dept of Microbiology, Temple University, Philadelphia, USA
- Novartis Oncology group, Basel, Switzerland
- Dept of Pharmacology, University of Oxford, UK
- Dept of Oral biology, UCSF, San Francisco, USA
- International Conference of Stem Cell Differentiation and Reprogramming, Santorini, Greece
- 7th EACPT Summer School in Clinical Pharmacology and Therapeutics, Alexandroupolis, Greece
- National Research Foundation, Athens
- EKEFE, Demokritos, Athens
- International Meeting on Biosimilars, Berlin
- Bodosakis Symposium, Brabrona, Attiki, Greece
- European Medicine Agency Workshop on Stem Cells, London, UK
- Hungarian Academy of Science Conference on Stem Cells(2011)
- Eurobic 10, Thessaloniki, Greece (2011)
- Stem cell Symposium, Bioacademy Athens, 2012
- International Society for Cell Therapy, Seattle,USA 2012
- University of Crete Medical School, Iraklio,2012
- International Society for Cell therapy (South American Division(, Buenos Aires, Agrentina 2012
- International Debate on Cardiovascular regeneration, Barcelona, Spain, 2012

- 7th Marie Curie Meeting in Kallithea Chalkidiki, Greece 2013
- 5th BBBB Meeting on Drug Strategies , Athens, Greece, 2013

Research Projects Funded in the last 10 years

- STEMNET (EPAN): Development of Stem cell Technologies in Greece: Stem Cell based therapies for regenerative medicines (PI/coordinator): Prof. S. Georgatos, University of Ioannina, Greece. Collaborative group: AUTH, PI: Prof. A.S. Tsiftoglou). Awarded by GSRT, Athens, Greece (1-10-2003 up to 30-9-2006). Total budget: 300.000€
- PENED 99 ED 560: Cloning and Expression of genes encoding regulatory proteins: biotechnological development and applications of systems producing heterologous peptides. (3 groups were involved: AUTH/ IMBB / Hellenic Paster Institute). PI/coordinator: Prof. A.S. Tsiftoglou, 18th months projects, starting 1999 up to 2001. Total budget: ~140.000€.
- 97EKBAN-2-17: Development and industrial production of human recombinant Protein Therapeutics as biotechnology products. Funded by GSRT / Athens (3 groups were involved: AUTH/ IMBB Crete / BIOSER SA, Trikala). Total budget: 247.500€ (1999 up to 2002) PI/coordinator: Prof. A.S. Tsiftoglou
- IRAKLEITOS: Role of mitochondrial proteins in pathophysiology and therapy of degenerative disorders. Ministry of Education, Program for studentships for basic research. (2002 up to 2005) Total Budget: 73.400€. PI/coordinator: Prof. A.S. Tsiftoglou
- EATRIS-GR Translational Research (as collaborative group) PI. A, Estratiadis (IBEAA)

Supervision of Doctorate and Master Graduate Students -Contribution to Graduate Program at Aristotle University of Thessaloniki

Eleven (11) graduate students were awarded Doctorate degree and other Six (7) got their Master degree in Pharmacology under the supervision of Prof. Asterios S. Tsiftoglou since early 90's up to today. All of them worked in the Laboratory of Pharmacology established by Prof. A.S. Tsiftoglou in the Dept. of Pharmacy in the middle 1980's

Current Research Interests

- Molecular analysis of erythropoiesis at transcriptional level-Identification of Transcription Complexes regulated by hemin
- Mesenchymal Stem Cell Differentiation process-Stem cell based Therapies
- Heme as regulator of leukemic stem cell renewal.. Interactions between MSCs and LSCs. Interacellular delivery of Proteins as Protein therapeutic Approach of Metabolic Disorders

Books written or edited , by Prof. A.S, Tsiftoglou

A.S, Tsiftoglou, A.C. Sartorelli et al., Tumor Biology: Regulation of Cell Growth, Differentiation and Genetics in Cancer, Springer, Berlin 1995

A.S. Tsiftoglou Handbook in Toxicology entitled Basic and Clinical Toxicology (Greek Edition), Art of Text publisher, Thessaloniki, 1997

A.S. Tsiftoglou Molecular and Clinical Pharmacology, Vol.I Published by University Studio Press, Thessaloniki, 2009 (Greek Edition)

PUBLICATIONS (published papers and chapters)

1. Tsiftoglou A. S., Georgatsos J. G. Metabolism of nucleosides by isolated mouse liver mitochondria. **Biochem. Biophys. Acta.** 1972; 262-239.
2. Sartorelli A. C., Agrawal K. C., Tsiftoglou A. S., Booth B. A. and Moore E. C. Approaches to the development of a second generation of a-(N)-heterocyclic carboxyaldehyde thiosemicarbazones with antineoplastic activity. **Experta Medical International Congress Series No. 353**, 1974, 5:230.
3. Tsiftoglou A. S., Hwang K. H., Agrawal K. C. and Sartorelli A. C. Strand scission of sarcoma tumor cell DNA induced by 1-formyl- isoquinoline thiosemicarbazone. **Biochem. Pharmacol.** 1975; 24:1631.
4. Sartorelli A. C., Agrawal K. C., Tsiftoglou A. S. and Moore E. C. Characterization of the biochemical mechanisms of action a-(N)-heterocyclic carboxyldehde thiosemicarbazones. **Advances in Enzyme Regul.** 1976; 15:117.
5. Li CD, Rittman L. S., Tsiftoglou A. S., Bhargava K. K. and Sartorelli A. C. Pyridine derivatives as potent inducers of erythroid differentiation of Friend leukemia cells. **J. Med Chem.** 1978; 21: 875.
6. Fondy T., Roberts S. B., Tsiftoglou A. S. and Sartorelli A. C. Haloacetamido-analogues of 2-amino-2-deoxy-D-glucose and 2-amino-2deoxy-D-galactose: Syntheses and effects on Friend Murine erythroleukemia cells. **J. Med. Chem.** 1978; 21: 1222.
7. Fondy T., Tsiftoglou A. S., Jacoby R. O. and Sartorelli A. C. Immunogenicity of Friend erythroleukemia cells altered in culture by chemical and physical agents. **Cancer Res.** 1979; 39: 3583.
8. Tsiftoglou A. S. and Sartorelli A. C. Dimethylsulfoxide (DMSO) - Induced erythroid differentiation of Friend leukemia cells in the absence of cytokinesis. **Cancer Res.** 1979; 39: 4058).
9. Tsiftoglou A. S., Barnett R., Sartorelli A. C. Enucleation of differentiated murine erythroleukemia cells in culture. **Proc. Natl. Acad. Sci. USA**, 1979; 76: 6381.
10. Tsiftoglou A. S., Gusella J. F., Volloch V., Housman D. Inhibition of the commitment to erythroid differentiation in murine leukemia cells by dexamethasone. **Cancer Res.** 1979; 39: 3849.
11. Tsiftoglou A. S., Kyriakidis D. Early changes in ornithine decarboxylase activity during Friend leukemia cell differentiation. **Biochem. Biophys. Acta.** 1979; 588: 279.
12. Housman D., Levenson R., Volloch V., Tsiftoglou A. S. Gusella J., Parker D., Kernen J., Mitrani A., Weeks V., Witte O., Besmer P. Control of proliferation and differentiation in Friend virus transformed cells. **Cold Spring Harbor Quant Biol.** 1979; 44: 1177.
13. Housman D., Volloch V., Tsiftoglou A. S., Levenson R., Gusella J. F., Mitrani A., Analysis of the molecular basics of commitment in murine erythroleukemia cells (MEL). In: Rossi G. ed. **In Vitro and In Vivo Erythropoiesis: The Friend System.** Amsterdam: Elsevier North-Holland Publishing Co., EMBO Conference, Italy, 1980; pp. 273-282.
14. Gusella J. F., Weil S., Tsiftoglou A. S. Volloch V., Newman J., Keys C., Housman D. Hemin does not cause commitment of MEL cells. **Blood.** 1980; 56: 481.
15. Tsiftoglou A. S., Bhargava K. K., Rittman L. S., Sartorelli A. C. Distribution of the inducer of differentiation bis-acetyl-diamino-pentane (BADP) in murine erythroleukemia cells. **J. Cell Physiol.** 1981; 106: 419.

16. Tsiftoglou A. S., Sartorelli A. C., Relationship between cell replication and erythroid differentiation of murine erythroleukemia cells in vitro. **Biochem. Biophys. Acta.** 1981; 653: 226.
17. Tsiftoglou A. S., Mitrani A., Housman D., Procaine inhibits the erythroid differentiation on MEL cells by blocking commitment: Possible involvement of calcium metabolism. **J. Cell Physiol.** 1981; 108:327.
18. Tsiftoglou A. S., Sartorelli A. C. Changes in surface architecture during murine erythroleukemia cell differentiation as detected by lectin binding and agglutination. **Biochem. Biophys. Acta.** 1981; 649: 105.
19. Rittman L. S., Jelsema C., Schwartz E., Tsiftoglou A. S., Sartorelli A. C. Lipid composition in Friend erythroleukemia cells following cell differentiation with dimethylsulfoxide. **J. Cell Physiol.** 1982; 110: 50.
20. Tsiftoglou A. S., Wong W., Minden M., Robinson S. H. Clonal and biochemical analysis of HL-60 cells committed differentiation. **Ann NY Acad Sci.** 1982; 397: 322.
21. Gusella J. F., Tsiftoglou A. S. Volloch V., Weil S., Newman J., Housman D. Dissociation of hemoglobin accumulation and commitment during murine erythroleukemia cell differentiation by treatment with imidazole. **J. Cell Physiol.** 1982; 113: 179.
22. Tsiftoglou A. S., Wong W., Volloch V., Gusella J. F., Housman D. Commitment of murine erythroleukemia cells to terminal differentiation is associated with coordinated expression of globin and ribosomal genes. **In: Cell Function and Differentiation. Prog. Clin. Biol. Res.** 1982; 102: 69-79.
23. Tsiftoglou A. S., Wong W., Housman D. Dexamethasone-sensitive and -insensitive responses during in vitro murine erythroleukemia cell differentiation. **Biochem. Biophys. Acta.** 1983; 759: 160.
24. Tsiftoglou A. S., Nurez M. T. Wong W., Robinson S. H. Dissociation of iron-transport and heme biosynthesis from commitment to terminal maturation of murine erythroleukemia cells. **Proc. Natl. Acad. Sci. USA.** 1983; 80: 758.
25. Tsiftoglou A. S., Robinson S. H. Differentiation of leukemic cell lines: a review focusing on murine erythroleukemia and human HL-60 cells. **Intl J. Cell Cloning** 1985; 3: 349-366.
26. Steinberg H. N., Tsiftoglou A. S., Robinson S. H. Loss of suppression of normal bone marrow colony formation by human leukemic cell lines after differentiation induction by chemical agents. **Blood** 1985; 65: 100-106.
27. Tsiftoglou A. S., Wong W. Molecular and cellular mechanisms of leukemic hemopoietic cell differentiation: an analysis of the Friend system. **Anticancer Res.** 1985; 5: 81-100.
28. Tsiftoglou A. S., Wong W., Hyman R., Minden M., Robinson S. H. Analysis of commitment of human leukemia HL-60 cells to terminal granulocytic maturation. **Cancer Res.** 1985; 45: 2334-2339.
29. Wong W., Robinson S. Tsiftoglou A. S. Relationship of mitochondrial membrane potential to hemoglobin synthesis during friend cell maturation. **Blood** 1985; 66: 999-1001.
30. Tsiftoglou A. S., Wong W., Housman D. The steroid-induced inhibition of commitment of murine erythroleukemia cells involves a glucocorticoid receptor-mediated process(es) acting at the nuclear level. **Biochimica Biophysica Acta** 1986; 889: 251-261.
31. Tsiftoglou A. S., Wong W., Wheeler C., Steinberg H. and Robison S. H. Prevention of adriamycin-induced cytotoxicity in hemopoietic cells by hemin. **Cancer Res.** 1986; 46: 3436.
32. Tsiftoglou A. S., Hensold J., Robinson S. H. and Wong W. The regulatory role of commitment in gene expression during induction of leukemic cell differentiation. In **"New Avenues in Developmental Cancer Chemotherapy"**, Vol. 8 of **Bristol-Myers Cancer Symposium Series**, Eds: **K. R. Harrap and T. A. Connors.** Academic Press, Inc., Florida, 1987; 8: 205-22.
33. Tsipis C. A., Shakhathreh S. K., Bakalbassis E. R. G., Pappas I. S. and Tsiftoglou A. S. Structure, magnetic properties and antineoplastic activity of novel phthalobridged copper (II) complexes. **Proceedings of the 5th International Symposium on Platinum and other metal coordination compound in Cancer Chemotherapy**, Martinus Nijhoff, Publishing Co., Boston, MA, p. 749-756, 1987.

34. Tsiftoglou A. S., Wong W. and Robinson S. H. Analysis of hemin-induced protection of human hemopoietic cells from the cytotoxic effects of anthracyclines. **Cancer Res.**, 48: 3566-3570, 1988.
35. Mylonas S., Valavanidis A., Dimitropoulos K., Polissiou M., Tsiftoglou A. S. and Vizirianakis J. S. Synthesis, molecular structure, determination and antitumor activity of platinum (II) and palladium (II) complexes of 2-substituted benzimidazoles- **J of Inorg. Biochem.**, 34: 265-275, 1988.
36. Papadopoulou L. C., Wheeler C. and Tsiftoglou A. S. Possible role of mitochondrial components in adriamycin-induced cytotoxicity of human leukemia cells. **J of Chemotherapy 1:** (suppl. 4) 1151-1154, 1989.
37. Gennimata D., Kotali E., Varvoglis A., Kyriakides D. and Tsiftoglou A. S. A di-thiocarbamido-derivative of 2,2-diphenylenyl - iodonium salt as a potent antibacterial agent. **J of Chemotherapy 1:** 229-232, 1989.
38. Tsiftoglou A. S., Wong W., Robinson S. H. and Hensold J. Hemin increases production of β -like globin RNA transcripts in human Erythroleukemia K-562 cells. **Developmental Genetics 10:** 311-317, 1989.
39. Mylonas S., Caranikas S., Polissiou M., Hatzigiannakou A., Tsiftoglou A. S. and Christou I. Synthesis, molecular structure, determination and antitumor activity of platinum (II) and palladium (II) complexes with carrier molecules derivatives of 3-(2-amonoethyl)-propionic acid peptides. **Proceedings of the First International Symposium on Metal Ions in Biology and Medicine**, Eds: P. Collery, L. A. Poirier, M. Manfait, J.-C. Etienne, John Libbey Publishing Co., London 1990, p. 357-359.
40. Davies J., Freyssinet G., Tsiftoglou A. S., Gürrevo R., Pühler A. Studies of interspecific gene transfer, maintenance and expression in nature. **In "Biotechnology R and D in the EC: Biotechnology Action Program" part I**, Ed. I. Economidis, Commission of the European Communities, p. 51-61, 1990.
41. Tsiftoglou A. S., Wong W., Tsamadou A. and Robinson S. H. Cooperative effects of hemin and antracyclines in inducing erythroid maturation in human K-562 leukemia cells. **Experimental Hematol.** 19: 928-933, 1991.
42. Tsiftoglou A. S., Pappas I. S. and Niopas I. D. Structural, cellular and pharmacological implications of neoplastic cell differentiation induced by ureido-derivatives of pyridine (UDPs). **In "Topics in Molecular Organization and Engineering"**, Eds: E. Rizzarelli and T. Theophanides, Kluwer Academic Publishers, Netherlands, 1991, p. 189-208.
43. Pappas I. S., Niopas I., and Tsiftoglou A. S. Ureido-derivatives of pyridine: A new class of inducers of murine erythroleukemia cell differentiation. **Anti-Cancer Drug Design**, 7: 153-161, 1992.
44. Vizirianakis J. S., Wong W. and Tsiftoglou A. S. Analysis of inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation induced by N⁶methyl Adenosine. **Biochem. Pharmacol.** 1992 44: 927-936.
45. Tsamadou A. I., Wong W. and Tsiftoglou A. S. Hemin uptake and Detection of Hemin Binding proteins (HeBP) in human Leukemia K 562 cells. **Proceedings of the Second International Symposium on Metal Ions in Biology and Medicine"** Eds. J. Anastasopoulou, P. Collery and T. Theophanides, John Libbey Eurotex Limited, Publishing Co., Pans. p. 145-150, 1992.
46. Tirodimos I., Pretorius - Güth I. M., Pühler A., Tsaftaris A. and Tsiftoglou A. S. Methods of Assesment of transfer of a Gentamycin resistance gene (aacC1) from Genetically Important Soil Bacteria. **Applied Microbiol. and Biotechnology** 38: 526-530 (1993).
47. Papadopoulou L. C. and Tsiftoglou A. S. Interactions of hemin and anthracyclines with mitochondrial cytochrome c-oxidase. **Proceedings of the 8th Mediterranean Congress of Chemotherapy**, 1993 In the press.
48. Gennimata D., Davies J. and Tsiftoglou A. S. Genotypic analysis of bleomycin resistance (Ble^R) in staphylococci. **Proceedings of the 8th Mediterranean Congress of Chemotherapy**, 1993 In the press.
49. Papadopoulou L. C. and Tsiftoglou A. S. Mitochondrial Cytochrome C-oxidase as Target site for daunomycin in K-562 cells and heart tissue. **Cancer Res.** 53: 1-7, 1993.

50. Tsiftoglou A. S., Tsamadou A. I., Robinson S. H. and Wong W. Hemin is transported in human leukemia K562 cells and interacts with DNA sequences. In **"Specific Approaches in Cancer Therapy: Differentiation, Immunomodulation and Angiogenesis"** NATO-ASI Series, Life Sciences Eds: N. D'Alessandro, L. Rausa and H-Tapiero, 1993 p. 108-120.
51. Tsiftoglou A. S. and Pappas I. Analysis of commitment of murine erythroleukemia cells to terminal maturation. In **"Molecular Biology of Hematopoiesis"**. Vol. III, Ed. by N. Abraham et.al. Intercept Press, 1993. p 169-176.
52. Vizirianakis A. S., Tsiftoglou A. S. and Sklaviadis T. S. Development in Slow Virus Research: Implications of PRP protein involvement in Cell Growth and Differentiation In **"Transmissible Spongiform Encephalopathies"** Ed. by E. Brandley and B. Merchant, Commission of the European Communities, 1993, D. 421-429.
53. Christou I. E. and Tsiftoglou A. S. Posttranscriptional Regulation of poly A⁺ RNA stability in Murine Erythroleukemia Cells by dexamethasone. **Mol. Cellul. Different.** 2(4): 329-349, (1994).
54. Thompson C. J., Guerrero R., Pühler A., Simonet P., Tsiftoglou A. S. and Lebrun M. Analysis of gene transfer between microorganism(s) and plants. Ed. by A. Vassaroti (**Biotechnology Research for Innovation, Development and Growth in Europe**) (BRIDGE) **Final Report 1994, Vol. II, p. 451-457.**
55. Vizirianakis I. S. and Tsiftoglou A. S. N⁶-methyladenosine Inhibits Murine Erythroleukemia Cell Maturation by blocking Methylation of RNA and Memory via Conversion to 5-(N⁶methyl)adenosylhomocysteine (1995) **Biochem. Pharmacol., 50: 1807-1814.**
56. Vizirianakis I. S. and Tsiftoglou A. S. Hypermethylation of RNA as part of the differentiation program of murine erythroleukemia (MEL) Cells (1995) In **"Challenges of Modern Medicine"** Eds. S. Waxman et. al. Serono Symposia Series, Vol. 10, p. 264-268,
57. Tsiftoglou A. S. Multidrug Resistance (MDR) in Tumors: Mechanism(s) and Trends in Cancer Chemotherapy In **Advances in Medical Oncology"** Proceedings of the European School Oncology Meeting, Chalkidiki, Greece, 1995, p. 13-17.
58. Pappas I. S. and Tsiftoglou A. S. Inducer Receptor Mediated Processes in Murine Erythroleukemia Cell Differentiation In **"Challenges of Modern Medicine"** (1995), Eds. S. Waxman et al, Serono Symposia Series, Vol. 10, p. 269-273.
59. Licht J. and Tsiftoglou A. S. Mechanism(s) of Leukemic Cell Differentiation In **"Challenges in Modern Medicine"** (1995), Eds. S. Waxman et al Serono Symposia Series, Vol. 10, p. 275-281.
60. Tsiftoglou A. S. and Vizirianakis I. S. Regulation of Murine Erythroleukemia Cell Differentiation In **"Regulation of Cell Growth, Differentiation and Genetics in Cancer"** NATO ASI Series, Eds: A. S. Tsiftoglou et al Springer-Verlag Press, 1995, In the Press.
61. Gennimata D., Davies J. and Tsiftoglou A. S. Bleomycin resistance (Ble^R) in *Staphylococcus aureus* clinical isolate **J. Antim. Chemoth.** 37: 65-75 (1996).
62. Vizirianakis I. S. and Tsiftoglou A. S. Induction of murine Erythroleukemia cell differentiation is associated with methylation and differential stability of polyA⁺RNA transcripts **Biochimica Biophysica Acta (BBA) 1312: 8-20** (1996).
63. Papadopoulou L. C. and Tsiftoglou A. S. Effects of Hemin on Apoptosis, Suppression of Cytochrome C oxidase Genes and Bone Marrow Toxicity Induced by Doxorubicin (Adriamycin) **Biochem. Pharm.** 52: 713-722 (1996).
64. Pappas I. S., Sophianos D., Tzartos S. and Tsiftoglou A. S. Expression of memory, differentiation and repression of c-myc and p53 genes in human RD/TE-671 cells induced by an ureido derivative of pyridine (UDP-4). **Cell Growth and Differentiation 7: 797-809** (1996).
65. Tassios P. T., Vatopoulos A. C., Mainas E., Gennimata D., Papadakis J., Tsiftoglou A. S., Kalapathaki V. and Legakis N. T. Molecular analysis of ampicillin-resistant sporadic *Salmonella typhi* *Salmonella paratyphi B* clinical isolates. **Clinical Microbiology and Infection, 3: 317-323.** (1997).
66. Lazos S. and Tsiftoglou A. S. Production of human IL-4 from a p-MAL expression vector in *E. Coli* Cells. **Medical Microbiology Letters**, vol. 5, Suppl. 1, 20, (1996).
67. Tsiftoglou A. S. Mechanisms of Multidrug Resistance (MOR) in Cancer: An Overview. **Review of Clinical Pharmacology and Pharmacokinetics: (International Edition) 12: 87-90** (1998).

68. Papadopoulou L. C., Theophilidis G., Thomopoulos G. N. and Tsiftoglou A. S. Assessment of structural and functional impairment of mitochondria involves suppression of COX II gene in adriamycin-induced cardiomyopathy in mice. **Biochem. Pharm.** **57: 481-489 (1999)**.
69. Vizirianakis I. S., Pappas I. S., Gougoumas D. and Tsiftoglou A. S. Expression of ribosomal protein S5 cloned gene during differentiation and apoptosis in Murine Erythroleukemia. (MEL) cells. **Oncology Research** **11: 409-419 (1999)**.
70. Vizirianakis I. S., Chen Y., Yao C. C., Ziober B. L., Tsiftoglou A. S. and Kramer R. H. Transfection of neoplastic cells with full-length human integrin alpha-7-DNA promotes cell adhesion *in vitro*. **Arch. Biochem. Biophys.** **385: 108-116 (2001)**.
71. Pozidis C., Lammertyn E., Politou S. A., Anné J., Tsiftoglou A. S., Sianidis G. and Economou A. Protein secretion biotechnology: large-scale production of functional tumor necrosis factor a using *Streptomyces lividans*. **Biotechnology and Bioengineering** **72: 611-619 (2001)**.
72. Pappas I., Vizirianakis I. S. and Tsiftoglou A. S. Cloning, Sequencing and Expression of a DNA encoding the mouse L35a ribosomal protein during differentiation of murine erythroleukemia (MEL) cells. **Cell Biology International** **25: 629-634 (2001)**.
73. Gougoumas D. D., Vizirianakis I. S. and Tsiftoglou A. S. Transcriptional activation of prion protein gene in growth arrested and differentiated mouse erythroleukemia and human neoplastic cells. **Exp. Cell Res.** **264: 408-417 (2001)**.
74. Tsiftoglou A. S., Kritis A., Brousalis-Tsiftoglou T., Dretaki P. and Pappas I. Production of Recombinant Human Cytokines from Genetically modified E. Coli cells via PCR technology and formulation as biopharmaceuticals. In "**2nd Hellenic Forum on Bioactive Peptides: Ed: By Typorama, Patras, Greece.**
75. Vizirianakis I. S., Pappas I. S., and Tsiftoglou A. S. Differentiation -dependent repression of c-myc, B22, COXII and COXIV genes in murine erythroleukemia (MEL) cells. **Biochem. Pharm.** **63: 1009-1017 (2002)**.
76. Vizirianakis I. S., Chen Y. Q., Kantak S. S. Tsiftoglou A. S. and Kramer R. H. Dominant-negative E-cadherin alters adhesion and reverses contact inhibition of growth in breast carcinoma cells. **Int. J. of Onc.** **20: 135-144 (2002)**.
77. Tsiftoglou A.S., Pappas I. and Vizirianakis I.S. The Developmental Program of Murine Erythroleukemia cells. **Oncology Res.** **13:339-346 (2003)**
78. Tsiftoglou A.S. , Pappas I.S. and Vizirianakis I.S. Mechanisms involved in the induced differentiation of leukemic cells. **Pharm. and Therap.** **100:257-290 (2003)**
79. Foltopoulou P. Zacharias G.A., Politou A.S. Tsiftoglou A.S., and Papadopoulou L.C. Human recombinant mutated forms of the mitochondrial COX assembly Sco2 protein differ from wild type in physical state and copper binding capacity. **Molecul. Genetics and Metab.** **81:225-236 (2004)**
80. Leontiadou F, Matragkou c, Kottakis D, Kalpaxis D.L., Vizirianakis I.S., Kouidou S, Tsiftoglou A.S. and Choli-Papadopoulou T. Genetic engineering of bacterial and eukaryotic ribosomal proteins for investigation on elongation arrest of nascent polypeptides and cell. In "**Methods in Proteome and protein analysis. Eds: R.M.Kamp, J.J. Calvete and T.Choli-Papadopoulou. Springer -Verlag Berlin Heidelberg, p.253-259 (2004)**
81. Vizirianakis IS and A.S.Tsiftoglou. Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)- RNA hybridized to 3'-end flanking sequences of β -major globin gene. **Biochim.Biophys. Acta,** **1743(1-2):101-114 (2005)**
82. Pappas IS, Lambris JD, Vizirianakis IS, Winters and Tsiftoglou AS. Mechanisms of action of differentiation inducers: detection of inducer binding protein in murine erythroleukemia cells. **Oncology Res.** **15(1):21-37 (2005)**
83. Bakopoulou AA, Triviai IN, Tsiftoglou AS, Garefis PD. In vitro assessment of cytotoxicity of resin-based dental restorative materials on WEHI 13 var fibroblasts. **Int J Prosthodont. Jan-Feb;****19(1):13-6(2006)**
84. Tsiftoglou AS, Tsamadou AI, Papadopoulou LC. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. **Pharmacol Ther.** **Aug;111(2):327-45. Epub 2006 Feb 28. (2006)**

85. Gougoumas D.D., Vizirianakis I.S, Triviari I.N and A.S.Tsiftoglou. activation of Prn-p gene and stable transfection of Prn-p cDNA in leukaemia MEL and Neuroblastoma N2a cells increased Production of PrPc but not Prevented DNA Fragmentation initiated by serum deprivation. **J. Cellular Physiol.** **211 (2):551-559 (2007)**
86. Bakopoulou, A., Tsiftoglou, A., Galaktidou, G., Markala, D., Triviari, I., Garefis, P. Patterns of cell death and cell cycle profiles of cultured WEHI 13 var fibroblasts exposed to eluates of composite resins used for direct and indirect restorations. **Eur. J. Oral Sci.** **115 (5):397-407 (2007)**
87. Tsiftoglou, A.S. Multiple exploitable molecular targets for differentiation therapy of leukemias. **Leukemia Res.** **32 (1):1-2 (2008)**
88. Bakopoulou, A., Mourelatos, D., Tsiftoglou, A.S., Mioglou, E., Garefis, P. Sister-chromatid exchange, chromosomal aberrations and delays in cell-cycle kinetics in human lymphocytes induced by dental composite resin eluates. **Mutat. Res.** **649 (1-2):79-90 (2008)**
89. Matragkou, C.N., Papachristou, E.T., Tezias, S.S., Tsiftoglou, A.S., Choli-Papadopoulou, T., Vizirianakis, I.S. The potential role of ribosomal protein S5 on cell cycle arrest and initiation of murine erythroleukemia cell differentiation. **J. Cellular Biochem.** **104 (4):1477-1490 (2008)**
90. Bakopoulou, A., Mourelatos, D., Tsiftoglou, A.S., Giassin, N.P., Mioglou, E., Garefis, P. Genotoxic and cytotoxic effects of different types of dental cement on normal cultured human lymphocytes. **Mutat. Res.** **672 (2):103-112 (2009)**
91. **Tsiftoglou AS**, Vizirianakis IS, Strouboulis J. Erythropoiesis: model systems, molecular regulators, and developmental programs. **IUBMB Life.** **2009 Aug;61(8):800-30.**
92. **Tsiftoglou AS**, Bonovolias ID, Tsiftoglou SA. Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy. **Pharmacol Ther.** **2009**, **122(3):264-80.**
93. Matragkou Ch, Papachristou H, Karetsou Z, Papadopoulos G, Papamarcaki T, Vizirianakis IS, **Tsiftoglou AS**, Choli-Papadopoulou T. On the intracellular trafficking of mouse S5 ribosomal protein from cytoplasm to nucleoli. **J Mol Biol.** **2009** **392(5):1192-204.**
94. Foltopoulou PF, **Tsiftoglou AS**, Bonovolias ID, Ingendoh AT, Papadopoulou LC. Intracellular delivery of full length recombinant human mitochondrial L- Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient' s primary cells **Biochim Biophys Acta.** **2010 Jun;1802(6):497-508**
95. Vizirianakis IS, Chatzopoulou M, Bonovolias ID, Nicolaou I, Demopoulos VJ, **Tsiftoglou AS**. Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives. **J Med Chem.** **14;53(19):6779-810 (2010) .**
96. Bakopoulou A, Leyhausen G, Volk J, **Tsiftoglou A**, Garefis P, Koidis P, Geurtsen W. Effects of HEMA and TEDGMA on the in vitro odontogenic differentiation potential of human pulp stem/progenitor cells derived from deciduous teeth. **Dent Mater** **2011;27(6):608-17.**
97. Bakopoulou A, Leyhausen G, Volk J, Tsiftoglou A, Garefis P, Koidis P, Geurtsen W. Comparative analysis of in vitro osteo/odontogenic differentiation potential of human dental pulp stem cells (DPSCs) and stem cells from the apical papilla (SCAP). **Arch Oral Biol.** **2011;56(7):709-21.**
98. Bakopoulou A, Leyhausen G, Volk J, **Tsiftoglou A**, Garefis P, Koidis P, Geurtsen W. Assessment of the impact of two different isolation methods on the osteo/odontogenic differentiation potential of human dental stem cells derived from deciduous teeth. **Calcif Tissue Int.** **2011;88(2):130-41.**
99. Papadopoulou LC, **Tsiftoglou AS**. Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders. **Pharm Res.** **2011 Nov;28(11):2639-56.**
100. In support of the European Union biosimilar framework. Schneider CK, Borg JJ, Ehmann F, Ekman N, Heinonen E, Ho K, Hoefnagel MH, van der Plas RM, Ruiz S, van der Stappen AJ, Thorpe R, Tiihonen K, Tsiftoglou AS, Vleminckx C, Waxenecker G, Welin M, Weise M, Trouvin JH; Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP); Biologicals

Working Party (BWP) of the Committee for Medicinal Products for Human Use (CHMP). **Nat Biotechnol.** 2012 Aug;30(8):745-8

101. Tezias SS, Tsiftoglou AS, Amanatiadou EP, Vizirianakis IS. Cloning and characterization of polyA- RNA transcripts encoded by activated B1-like retrotransposons in mouse erythroleukemia MEL cells exposed to methylation inhibitors. **BMB Rep.** 2012;45(2):126-31.
102. Chatzopoulou M, Bonovolias ID, Nicolaou I, Demopoulos VJ, Vizirianakis IS, Tsiftoglou AS. Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides. **Eur J Med Chem.** 2012;50:75-80.
103. Vizirianakis IS, Tezias SS, Amanatiadou EP, Tsiftoglou AS. Possible interaction between B1 retrotransposon-containing sequences and β (major) globin gene transcriptional activation during MEL cell erythroid differentiation. **Cell Biol Int.** 2012;36(1):47-55.
104. Tsiftoglou AS, Ruiz A. Development and regulation of Biosimilars: Current status and future challenges. **Biodrugs** 2013 (in press).
105. Papadopoulou LC, Tsiftoglou AS. The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders. **Pharmaceuticals** 2013;6(1):32-53.

Prof. Asterios S. Tsiftoglou has also published more than 100 abstracts submitted into International meetings abroad. These abstracts are not listed here due to space restrictions.